FIGHT-101:强效选择性FGFR 1-3抑制剂培米替尼在伴FGF/FGFR改变的泛癌种晚期恶性肿瘤患者中的首次人体研究
FIGHT-101为I/II期首次人体研究,纳入128例晚期恶性肿瘤患者,评估培米替尼单药或联合治疗的安全性、药代动力学、药效动力学及初步疗效。未报告剂量限制性毒性,最大耐受剂量未达到,推荐II期剂量为13.5 mg每日一次。常见治疗中出现的不良事件为高磷血症(75.0%),12例部分缓解,FGFR融合/重排患者客观缓解率最高(25.0%)。
要点
- 培米替尼1-20 mg每日一次间歇或持续给药,未报告剂量限制性毒性,最大耐受剂量未达到,推荐II期剂量13.5 mg每日一次。
- 最常见治疗中出现的不良事件为高磷血症(75.0%;≥3级2.3%),最常见≥3级不良事件为乏力(10.2%)。
- 12例部分缓解,FGFR融合/重排患者客观缓解率25.0%,FGFR突变患者23.1%,中位缓解持续时间7.3个月。
核心结论
- 培米替尼具有可控的安全性特征及药效动力学和临床活性,缓解见于多种肿瘤,且由FGFR融合/重排和突变驱动。
- 上述结果促成胆管癌注册研究及多种肿瘤类型的II/III期试验,证明精准治疗的获益,即使在早期试验中亦然。
研究设计与样本
- I/II期FIGHT-101研究(NCT02393248),评估培米替尼单药或联合治疗在伴或不伴FGF/FGFR基因改变的难治性晚期恶性肿瘤中的安全性、药代动力学、药效动力学及初步疗效。
- 第1部分为剂量递增(3+3设计),纳入分子学未选择的晚期恶性肿瘤患者,确定最大耐受剂量。
- 第2部分为剂量扩展,在FGF/FGFR活性相关的肿瘤中评估推荐II期剂量。
- 共128例患者接受培米替尼1-20 mg每日一次间歇给药(用药2周停1周;n=70)或持续给药(n=58)。
主要发现
- 未报告剂量限制性毒性;≥4 mg剂量具有药理学活性,最大耐受剂量未达到,推荐II期剂量为13.5 mg每日一次。
- 最常见治疗中出现的不良事件为高磷血症(75.0%;≥3级2.3%);最常见≥3级治疗中出现的不良事件为乏力(10.2%)。
- 剂量中断、剂量降低和治疗中出现的不良事件相关治疗终止分别发生于66例(51.6%)、14例(10.9%)和13例(10.2%)患者。
- 共12例部分缓解,最常见于胆管癌(n=5),另见于头颈、胰腺、胆囊、子宫、尿路上皮癌、复发性毛细胞星形细胞瘤和非小细胞肺癌(各n=1);中位缓解持续时间为7.3个月(95%CI 3.3-14.5个月)。
- FGFR融合/重排患者客观缓解率最高(n=5;25.0%,95%CI 8.7%-49.1%),其次为FGFR突变患者(n=3;23.1%,95%CI 5.0%-53.8%)。
关键数值与推荐
- 推荐II期剂量为13.5 mg每日一次。
- 间歇给药方案为用药2周停1周。
- FGFR融合/重排患者客观缓解率为25.0%(95%CI 8.7%-49.1%),FGFR突变患者为23.1%(95%CI 5.0%-53.8%)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase I/II FIGHT-101 study (NCT02393248) evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of pemigatinib, a potent and selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor, as monotherapy or in combination therapy, for refractory advanced malignancies, with and without fibroblast growth factor (FGF) and receptor (FGFR) gene alterations. PATIENTS AND METHODS: Eligible, molecularly unselected patients with advanced malignancies were included in part 1 (dose escalation; 3 + 3 design) to determine the maximum tolerated dose. Part 2 (dose expansion) evaluated the recommended phase II dose in tumors with or where FGF/FGFR activity is relevant. RESULTS: Patients (N = 128) received pemigatinib 1-20 mg once daily intermittently (2 weeks on/1 week off; n = 70) or continuously (n = 58). No dose-limiting toxicities were reported. Doses ≥4 mg were pharmacologically active (maximum tolerated dose not reached; recommended phase II dose 13.5 mg once daily). The most common treatment-emergent adverse event (TEAE) was hyperphosphatemia (75.0%; grade ≥3, 2.3%); the most common grade ≥3 TEAE was fatigue (10.2%). Dose interruption, dose reduction, and TEAE-related treatment discontinuation occurred in 66 (51.6%), 14 (10.9%), and 13 (10.2%) patients, respectively. Overall, 12 partial responses were achieved, most commonly in cholangiocarcinoma (n = 5) as well as in a broad spectrum of tumors including head and neck, pancreatic, gallbladder, uterine, urothelial carcinoma, recurrent pilocytic astrocytoma, and non-small-cell lung cancer (each n = 1); median duration of response was 7.3 months [95% confidence interval (CI) 3.3-14.5 months]. Overall response rate was highest for patients with FGFR fusions/rearrangements [n = 5; 25.0% (95% CI 8.7% to 49.1%)], followed by those with FGFR mutations [n = 3; 23.1% (95% CI 5.0% to 53.8%)]. CONCLUSIONS: Pemigatinib was associated with a manageable safety profile and pharmacodynamic and clinical activity, with responses seen across tumors and driven by FGFR fusions/rearrangements and mutations. These results prompted a registrational study in cholangiocarcinoma and phase II/III trials in multiple tumor types demonstrating the benefit of precision therapy, even in early phase trials.
引用
- Subbiah V, Iannotti NO, Gutierrez M, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022. PMID: 35176457. doi:10.1016/j.annonc.2022.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。